In solid tumors, MSI2 has been shown to promote non-small cell lung cancer (NSCLC) metastasis via TGF-β signaling [14], and promote pancreatic cancer development and drug resistance [15, 16]. This evidence concerns the gene MSI2 and non-small cell lung carcinoma.